Psilocybin Drug Interactions: SSRIs, Lithium, MAOIs & More

Psilocybin is one of the safer mind-active drugs in the body. But three medications are truly dangerous to combine with it. Lithium can trigger seizures. MAOIs can push the experience to harmful levels. Tramadol raises the risk of serotonin syndrome. This guide sorts every common medication into four groups — dangerous, risky, blunting, or safe — and names the source for each.

Published April 2026

Chief Bear · ~12 min read

How Psilocybin Interacts With Other Drugs

When you take psilocybin, your liver rapidly dephosphorylates it to psilocin — the active metabolite (Nichols, 2016, Pharmacological Reviews). Psilocin binds primarily to serotonin 5-HT2A receptors on cortical pyramidal neurons, with weaker activity at 5-HT2C and 5-HT1A receptors. It is metabolized by monoamine oxidase (MAO) and glucuronidation, then cleared in urine within hours.

That pharmacology is why most clinically meaningful interactions fall into four categories:

1. Serotonergic potentiation (dangerous): MAOIs prevent psilocin breakdown; tramadol adds serotonergic load → overwhelming intensity, hypertensive responses, theoretical serotonin syndrome.
2. 5-HT2A occupancy or downregulation (blunting, not dangerous): SSRIs, SNRIs, TCAs, atypical antipsychotics. Chronic use desensitizes or blocks psilocybin's target receptor, so the experience is dampened or absent.
3. Non-serotonergic pharmacological risk (dangerous): Lithium interacts with psilocybin in ways still poorly understood mechanistically, but the clinical signal is clear — seizure case reports (Nayak et al., 2021, Psychopharmacology).
4. Psychological / behavioral interactions (low physiological risk): Cannabis, alcohol, and stimulants don't cause dangerous pharmacological reactions but meaningfully change the experience — usually for the worse in a therapeutic context.

The sections below cover the 10 medication classes most commonly asked about. If your medication is not listed, the default rule is: ask a prescribing clinician before combining anything with psilocybin. Drug-interaction data for psilocybin is still incomplete, and absence of a warning is not proof of safety.

At-a-Glance Risk Table

SSRIs (Sertraline, Escitalopram, Fluoxetine, etc.)

Selective serotonin reuptake inhibitors raise synaptic serotonin. Over weeks of daily use, postsynaptic 5-HT2A receptors compensate by downregulating — the same receptor psilocin needs to activate to produce its effects. The result is a blunted psilocybin experience: lower intensity, shorter duration, and for many people essentially no subjective effect at standard clinical doses (Bonson et al., 1996, Neuropsychopharmacology).

There is no evidence of dangerous serotonergic potentiation between psilocybin and SSRIs. Psilocybin does not inhibit serotonin reuptake and does not add significant serotonergic load. Serotonin syndrome is a theoretical concern raised in older literature but has not materialized in published case reports from the modern clinical trial era, in which SSRI-experienced participants are routinely tapered and dosed safely.

Clinical trial protocols (Compass Pathways COMP360, Usona Institute) require participants to taper SSRIs 2–6 weeks before dosing depending on the specific drug's half-life. Fluoxetine (Prozac) has the longest half-life and typically requires a 4–6 week washout. Abrupt SSRI discontinuation causes SSRI discontinuation syndrome — dizziness, electric-shock sensations ("brain zaps"), severe mood instability, and rebound depression — so tapers must be gradual and supervised. See our psilocybin vs SSRIs guide for a full mechanism + efficacy comparison.

SNRIs & Tricyclic Antidepressants

Serotonin-norepinephrine reuptake inhibitors (venlafaxine, duloxetine) and tricyclic antidepressants (amitriptyline, nortriptyline, imipramine) share the SSRI mechanism of raising synaptic serotonin, plus additional norepinephrine and anticholinergic effects depending on the drug. The same 5-HT2A downregulation that blunts psilocybin on SSRIs blunts it on SNRIs and TCAs.

TCAs have a narrower therapeutic window than SSRIs and can lower seizure threshold at higher doses. Combining a high-dose TCA with psilocybin is theoretically concerning on seizure grounds, but there are no published case reports of seizures from this specific combination. The practical rule mirrors SSRI management: taper under medical supervision before any psilocybin session. Standard washout is 2 weeks for most SNRIs and 2–4 weeks for TCAs depending on dose and half-life.

MAOIs — Do Not Combine

Psilocin is partly metabolized by monoamine oxidase. MAOIs — phenelzine (Nardil), tranylcypromine (Parnate), selegiline (Emsam), moclobemide (Aurorix), and isocarboxazid (Marplan) — block that breakdown, causing psilocin blood levels to rise substantially and effects to last much longer than normal (Nichols, 2016, Pharmacological Reviews).

This interaction is the foundation of traditional ayahuasca: the brew combines DMT (broken down by MAO, normally orally inactive) with plants containing reversible MAO inhibitors (harmala alkaloids). A similar principle applies to psilocybin — MAO-inhibited mushroom experiences are reported as dramatically more intense, longer-lasting, and harder to manage. In an unsupervised or therapeutic context, this is not a feature, it is a hazard. Anecdotal reports include panic, psychological destabilization lasting days, and severe hypertensive responses.

Moclobemide is a reversible MAOI with a shorter washout (24–48 hours) than irreversible MAOIs, which require a 2-week washout. Selegiline at ADHD / Parkinsonian doses (>10 mg/day) is also dangerous to combine. Transdermal selegiline (Emsam) at higher doses loses its MAO-B selectivity and becomes a full MAOI risk.

Lithium — Seizure Risk

Lithium is a mood stabilizer used primarily for bipolar disorder. The mechanism of the psilocybin-lithium interaction is not fully understood — lithium doesn't act on serotonin receptors directly — but the clinical signal is unambiguous. Nayak and colleagues (2021, Psychopharmacology) reviewed self-reported outcomes from people who combined lithium with classic psychedelics and found a disproportionately high rate of seizures and severely negative psychological experiences compared to other medication combinations.

Lithium is an absolute exclusion criterion in every published psilocybin clinical trial. If you are on lithium, the practical guidance is clear: do not use psilocybin. If you are considering psilocybin therapy and currently take lithium, any transition must happen under psychiatric supervision with careful management of the underlying condition lithium is treating — often bipolar I disorder, which is itself a contraindication for psilocybin on separate psychosis-risk grounds.

Tramadol — Serotonin Syndrome Risk

Tramadol is an atypical opioid marketed as a "safer" analgesic. In reality it has a complex pharmacology that includes mu-opioid agonism, serotonin and norepinephrine reuptake inhibition, and weak MAO-A inhibition at higher doses — a profile that makes it uniquely problematic to combine with other serotonergic agents (FDA tramadol label; MAPS harm-reduction guidelines). Tramadol also independently lowers seizure threshold.

Combining tramadol with psilocybin risks both serotonin syndrome (agitation, hyperreflexia, autonomic instability, hyperthermia, seizures) and direct seizure induction independent of serotonin syndrome. Neither is acceptable. If you need ongoing analgesia and are considering psilocybin therapy, discuss non-serotonergic alternatives with a prescriber before any session.

Benzodiazepines — Clinical Rescue Medication

Benzodiazepines (lorazepam / Ativan, diazepam / Valium, alprazolam / Xanax, clonazepam / Klonopin) potentiate GABA-A inhibition, producing rapid-onset sedation and anxiolysis. They don't act on psilocybin's serotonin 5-HT2A target but their global sedating effect dampens the psilocybin experience acutely. A single oral dose of 1–2 mg lorazepam reliably reduces intensity within 30 minutes and is used in modern clinical trial protocols (Johnson et al., 2008, Journal of Psychopharmacology) as the preferred rescue medication for participants who become severely distressed during a session.

For chronic benzodiazepine users, the therapeutic experience is partially blunted — not dangerously, but meaningfully. Most clinical protocols require participants to hold benzos on session days and, where clinically feasible, taper before the treatment course begins. Benzo tapers must be slow and medically supervised because abrupt discontinuation can trigger seizures independent of any psilocybin use.

Stimulants (ADHD Medications)

Amphetamine-based stimulants (Adderall, Vyvanse, Dexedrine) and methylphenidate (Ritalin, Concerta) increase dopamine and norepinephrine release. Psilocybin independently produces a mild transient rise in heart rate and blood pressure. Combining the two stacks cardiovascular effects — tolerable in a medically-screened healthy adult, meaningful in anyone with borderline hypertension or cardiac history. Stimulants also amplify anxiety, overstimulation, and difficulty surrendering to the experience — all of which work against a therapeutic session.

Practical guidance from clinical protocols: hold stimulants on dosing day. Atomoxetine (Strattera) — a non-stimulant ADHD medication — acts on norepinephrine reuptake and has serotonergic activity, so it's treated like an SSRI in trial protocols and tapered over 2 weeks before sessions.

Antipsychotics — Abort Agent

Atypical antipsychotics (risperidone / Risperdal, olanzapine / Zyprexa, quetiapine / Seroquel, aripiprazole / Abilify, ziprasidone / Geodon) all have 5-HT2A receptor antagonism as part of their therapeutic mechanism. Vollenweider and colleagues (1998, NeuroReport) demonstrated that a single dose of ketanserin — a selective 5-HT2A antagonist — almost completely blocked psilocybin's subjective and objective effects in healthy volunteers, confirming 5-HT2A as the critical receptor. Clinically-used antipsychotics have this same antagonist property.

Practical implications: someone on chronic antipsychotic therapy will get little or no effect from a standard psilocybin dose, and emergency departments use intramuscular olanzapine or risperidone to abort severe psychedelic crises. Antipsychotics also independently treat the psychosis that makes psilocybin contraindicated in schizophrenia-spectrum patients — so the combination is primarily encountered in harm-reduction contexts rather than elective therapy.

Cannabis

THC acts on CB1 cannabinoid receptors, a mechanism unrelated to psilocybin's 5-HT2A target. There is no documented dangerous pharmacological interaction. What does happen consistently in self-reports and harm-reduction literature is that cannabis makes difficult psilocybin experiences more difficult — amplifying anxiety loops, paranoia, time dilation, and introspective overwhelm. The subjective intensity of the psilocybin experience often increases without a proportional increase in insight or therapeutic benefit.

Practical guidance: avoid cannabis during the first half of a psilocybin experience. If using cannabis recreationally with mushrooms, start with far less than a normal cannabis dose — the effects compound unpredictably and people who think they can handle their usual amount routinely cannot. Chronic heavy cannabis use may also dampen psilocybin's acute effects through endocannabinoid system feedback, though human data is limited. For context on why setting matters so much, see our safe trip guide.

Alcohol

Ethanol acts primarily on GABA-A and NMDA receptors — pharmacologically unrelated to psilocybin's serotonin 5-HT2A mechanism. No meaningful acute interaction has been documented. What makes alcohol a bad idea with psilocybin is behavioral and practical: it impairs the decision-making you need during a session, it compounds psilocybin's mild nausea, and it fragments the introspective quality of the experience that makes therapeutic work possible afterward.

Chronic heavy alcohol use alters the serotonin system and may partially blunt psilocybin's effects, though human data is limited. Notably, psilocybin-assisted therapy is itself under investigation as a treatment for alcohol use disorder — see our psilocybin for alcoholism guide for the clinical evidence. The context for that therapeutic use is a structured supervised program, not recreational co-administration.

How to Taper Safely Before a Session

Typical washout windows used in published clinical trial protocols:

• Fluoxetine (Prozac): 4–6 weeks — longest half-life among SSRIs
• Sertraline, citalopram, escitalopram, paroxetine: 2 weeks
• Venlafaxine, duloxetine (SNRIs): 2 weeks — paroxetine-like discontinuation risk; taper especially carefully
• TCAs (amitriptyline, nortriptyline): 2–4 weeks depending on dose
• Irreversible MAOIs (phenelzine, tranylcypromine): 2 weeks minimum
• Moclobemide (reversible MAOI): 24–48 hours
• Lithium: taper managed individually — the underlying condition dictates the plan
• Atomoxetine (Strattera): 2 weeks
• Benzodiazepines (chronic use): slow medically-supervised taper over weeks to months; never abrupt
• Stimulants (ADHD): typically just the dosing day is held

If you are working with a clinical trial, the screening team manages the taper. If you are considering supervised access in Oregon or Colorado, bring a medication list to your prescriber and ask directly: "What is the safe way to taper this before a psilocybin session, and what reinstatement plan do we have afterward?" Many general practitioners are unfamiliar with this question — seek a clinician experienced with psychedelic-assisted therapy if possible.

Key Takeaways

• Three hard contraindications — lithium, MAOIs, and tramadol. Each has a clear pharmacological basis and, for lithium, multiple published seizure case reports. These are not "caution" items; they are "do not combine."
• SSRIs, SNRIs, TCAs, and atypical antipsychotics are blunting, not dangerous. Chronic use downregulates or blocks 5-HT2A, the receptor psilocybin activates. Most people on these medications feel little or nothing from a standard psilocybin dose.
• Never stop psychiatric medications abruptly on your own. Discontinuation syndrome is real. Use a prescriber-supervised taper timed to the drug's half-life.
• Benzodiazepines and antipsychotics are the clinical rescue agents. Lorazepam 1–2 mg is the standard trial rescue for severe distress; IM olanzapine or risperidone will abort a trip in an emergency setting.
• Cannabis and alcohol are not dangerous pharmacologically, but they are disruptive. For any therapeutic-intent session, avoid both for at least 24 hours before and 24 hours after.
• If your medication isn't listed here, ask a prescriber. Psilocybin interaction data is still incomplete, and the absence of a warning is not proof of safety.

Frequently Asked Questions